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Abstract
: The ubiquitin system of protein modification has emerged as a crucial mechanism involved in the
regulation of a wide array of cellular processes. As our knowledge of the pathways in this system
has grown, so have the ties between the protein ubiquitin and human disease. The power of the
ubiquitin system for therapeutic benefit blossomed with the approval of the proteasome inhibitor
Velcade in 2003 by the FDA. Current drug discovery activities in the ubiquitin system seek to (i)
expand the development of new proteasome inhibitors with distinct mechanisms of action and
improved bioavailability, and (ii) validate new targets. This review summarizes our current
understanding of the role of the ubiquitin system in various human diseases ranging from cancer,
viral infection and neurodegenerative disorders to muscle wasting, diabetes and inflammation. I
provide an introduction to the ubiquitin system, highlight some emerging relationships between the
ubiquitin system and disease, and discuss current and future efforts to harness aspects of this
potentially powerful system for improving human health.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Broad overview of family
Overview of the ubiquitin system
The ubiquitin system is a hierarchical enzymatic cascade
in which a ubiquitin-activating enzyme (E1) activates the
76 amino acid protein UBIQ (ubiquitin) in an ATP-
dependent manner and transfers it to the active site
cysteine of ubiquitin-conjugating enzymes (E2s) [1].
Ubiquitin ligases (E3s) have a central role in the process
of protein modification with UBIQ (known as 'ubiquiti-
nation' or 'ubiquitylation'); they recognize specific sub-
strates and facilitate UBIQ transfer from the E2 onto the
substrate. Although the precise number of human E3s is
unknown, about 500 or more have been proposed to exist
[2-5], supportive of the broad role for the ubiquitin sys-
tem in regulating diverse cellular processes. Ubiquitin-like
proteins (UBLs) have also been identified with varying
degrees of identity to UBIQ and are conjugated onto pro-
teins through similar enzymatic cascades as UBIQ.
Numerous deubiquitylating enzymes (DUBs) have roles
in processing polyubiquitin precursor proteins and may
also have regulatory roles, e.g. counteracting the ubiquit-
ylation of a particular protein by its cognate E3 and/or
proofreading synthesized UBIQ chains. There are also
emerging roles for DUBs in disease (see [6]). Ubiquitin
binding proteins also have diverse functions and may rep-
resent viable therapeutic targets (see [7]). In a general
sense, they act as 'effector' proteins that sense a protein's
modification with UBIQ and facilitate downstream sign-
aling.
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Two major classes of E3s have been identified and this
classification is largely based on how they facilitate UBIQ
transfer from E2 onto substrate. HECT (homologous to
E6AP C-terminus) domain E3s form a catalytic UBIQ
intermediate on a conserved cysteine residue prior to cov-
alent UBIQ transfer (see [8]). The second class of E3s,
which contains RING-type and structurally related ligases,
facilitates the direct transfer of UBIQ from E2 onto sub-
strate. In general, E3s facilitate covalent UBIQ transfer by
properly positioning the site to be modified (i.e. a lysine
residue of its recognized substrate) such that it can per-
form nucleophilic attack of a thioesterified UBIQ mole-
cule either on the active site of the E2 for RING-type E3s
or on the conserved cysteine of HECT domain E3s, result-
ing in isopeptide bond formation [9].
Lysine residues appear to be major sites of UBIQ attach-
ment on proteins, although N-terminal and cysteine mod-
ifications have also been reported [10-17]. The type of
UBIQ modification could confer distinct encoded protein
fate and we are only beginning to understand how this
process occurs and how it is recognized and interpreted.
Mono-ubiquitylation (i.e. the attachment of a single
UBIQ molecule to a single site on a protein) may be
involved in histone regulation, receptor endocystosis and
signaling [18-22]. UBIQ chains using a lysine residue of
one UBIQ molecule attached via an isopeptide bond to
the C-terminus of another UBIQ molecule add further
complexity to UBIQ-encoded protein fate. Lys48-linked
UBIQ chains can trigger degradation by the 26S proteas-
ome [23-26] and Lys63-linked UBIQ chains may regulate
signaling pathways [27-30] when attached to a protein.
Other types of linkages (including those containing heter-
ogeneous mixtures of linkages or branched chains) could
also exist [31-33]; however their roles and physiological
significance are currently unclear.
Target validation
Implication of the ubiquitin system in human disease
The basic functions of the UBIQ (ubiquitin) protein were
first described in 1980 [34-36], yet its implication in
human disease has only recently started to become appre-
ciated. Below, I describe some relationships between the
ubiquitin system and various human diseases.
Cancer is associated with alterations in UBIQ-dependent 
regulation
The ubiquitin system has a widely appreciated role in reg-
ulating cellular proliferation. As expected and described in
the examples below, alterations in specific pathways
involving UBIQ have been associated with cancer.
The stability of P53 (p53) is regulated by ubiquitin ligases and a 
deubiquitylating enzyme (DUB)
The transcription factor P53 has a crucial role in cellular
anticancer mechanisms and it has been estimated that
>50% of tumors contain mutations in the P53 gene [37].
MDM2 is a major regulator of P53 function – it binds
directly to P53 and targets P53 for degradation through its
RING ubiquitin ligase activity [38-42]. MDM2-P53 bind-
ing, MDM2-dependent P53 degradation by the proteas-
ome, and P53 ubiquitylation by MDM2 have been
demonstrated in cell-based and in vitro systems by a large
number of groups.
P53 regulates the stability of the interaction between
MDM2 and the DUB known as UBP7 (also known as
USP7, HAUSP, herpesvirus-associated ubiquitin-specific
protease [43]) [44-47]. Work from the laboratory of Wei
Gu demonstrated that partial reduction of UBP7 by RNAi
in human cell lines (NHF-1, IMR90, U2OS and H1299
cells were tested) promotes decreased levels of both
MDM2 and P53 [45]. By contrast, however, total reduc-
tion of UBP7 decreases MDM2 yet stabilizes P53. This
observation suggests that the absence of UBP7 promotes
MDM2 downregulation, which in turn eliminates
MDM2's function as the ubiquitin ligase for P53. This
mechanism requires MDM2-dependent function, as
depletion of UBP7 in cells inactive for MDM2-dependent
P53 turnover (i.e. HeLa cells [48]) results in P53 stabiliza-
tion.
Cullin-RING ubiquitin ligases and the APC/C regulate cellular 
proliferation
Cullin-RING ubiquitin ligases (CRLs) and the anaphase-
promoting complex/cyclosome (APC/C) are multi-subu-
nit RING ubiquitin ligases that have fundamental roles in
controlling the eukaryotic cell cycle (see [49]). CRLs con-
tain a cullin protein (CUL1, CUL2, CUL3, CUL4A, CUL5,
CUL7) that binds within the cullin homology domain to
the RING protein RBX1 [50-52]. The distinct N-terminal
regions of the cullins interact with specific classes of sub-
strate receptors that promote the recruitment of a large
number of proteins for ubiquitylation [53]. The APC/C
consists of at least 11 subunits and has a mass of 1.5 mDa
[54,55]. One of its subunits, APC2, contains a domain
similar to cullins and associates with the RING protein
APC11, suggesting that its enzymatic core is similar to
CRLs [56-62].
The CUL1-based ubiquitin ligase known as SCF (SKP1-
CUL1-F-box) recognizes its substrates through various
receptor proteins containing the F-box motif [63]. The
SKP2 F-box protein, which functions with SCF in the
ubiquitylation of CDN1B (the cyclin-dependent kinase
inhibitor p27) at the G1/S transition of the cell cycle [64-
66], has garnered attention as a potential oncology target.BMC Biochemistry 2008, 9(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/9/S1/S7
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SKP2, in conjunction with the adapter protein CKS1, rec-
ognizes phosphorylated CDN1B late in G1, recruiting it
for ubiquitylation by SCF [67,68]. An inverse correlation
between SKP2 overexpression and low CDN1B levels has
been found in a variety of human tumors and transgenic
mouse models, and has led to the proposal that SKP2 is a
proto-oncogene [69-74].
The protein encoded by the tumor suppressor gene VHL
(von Hippel-Lindau) serves as a substrate receptor for a
CUL2-based ubiquitin ligase [50,75-80]. Mutations in
VHL are associated with lung cancer, sporadic clear cell
renal carcinomas and an autosomal dominant familial
cancer known as von Hippel-Lindau disease ([81-93] and
see [94]). Many of these mutations prevent VHL associat-
ing with the other subunits of its ubiquitin ligase, as
judged by in vitro binding and co-immunoprecipitation
experiments [79,80,95]. A substrate for this ubiquitin
ligase is a marker of tumor hypoxia, the transcription fac-
tor HIF1A (HIF1α, hypoxia-inducible factor 1α), which
stimulates angiogenesis [96]. Numerous biochemical and
structural studies have determined that HIF1A binds to
VHL when hydroxylated on two proline residues through
the activity of prolyl hydroxylases, which results in its
ubiquitylation and ultimate degradation [77,78,97-102].
Transgenic mice overexpressing a stabilized form of
HIF1A that cannot be recognized by VHL develop hyper-
vascularity without leakage or inflammation [103].
Cervical cancer is linked to HPV infection and involves 
downregulation of P53 and RB (Rb)
HPVs encode two oncogenic proteins known as E6 and
E7, and the sexually transmitted types of HPV have a
strong association with cervical cancer (see [104]).
Whereas E7 may facilitate the degradation of the tumor
suppressor RB through an unclear mechanism, the role of
E6 in cellular transformation is more established [105].
E6 binds to a cellular protein known as UBE3A (E6AP),
which is a HECT domain ubiquitin ligase [106]. This
interaction promotes the recruitment of the tumor sup-
pressor P53 to this complex, resulting in its ubiquitylation
and subsequent degradation by the 26S proteasome
[107,108].
Colorectal cancers are associated with defects in the regulation of 
CTNB1 (β-catenin) stability through mutations in adenomatous 
polyposis coli
The tumor suppressor gene adenomatous polyposis coli
(APC, not to be confused with the ubiquitin ligase APC/C,
anaphase-promoting complex/cyclosome, described
above) is frequently mutated in colorectal cancers [109-
114]. Many of these mutations truncate APC and/or alter
its ability to interact with proteins, which may lead to
altered regulation of cellular proliferation.
One major target subjected to regulation through APC is
CTNB1, a crucial component of Wnt signaling and cell
adhesion [115,116]. The phosphorylation of CTNB1
through APC-associated kinase activity promotes its rec-
ognition by the F-box protein β-TRCP [117,118]. Numer-
ous cell-based and in vitro experiments have demonstrated
that the F-box motif of β-TRCP interacts with SKP1 and
assembles into an SCF complex with CUL1 [63,117-119].
Overexpression of β-TRCP containing an F-box deletion
results in an increased stability of CTNB1, as demon-
strated in pulse chase experiments [117,119]. Other stud-
ies have identified the RING protein SIAH1 (a Drosophila
seven in absentia homolog) as a P53-inducible and APC-
associated ubiquitin ligase that can also regulate the sta-
bility of CTNB1 [120,121].
Mutations in the BRCA1 ubiquitin ligase complex correlate with 
breast and ovarian cancer
Germline mutations in the gene encoding the RING pro-
tein BRCA1 are associated with the inherited predisposi-
tion for breast and ovarian cancer [122-124]. BRCA1
forms a heterodimer with another RING protein known as
BARD1 and this complex has E3 activity in vitro [125-
128]. These studies, utilizing bacterially expressed pro-
teins and overexpression in mammalian cells, demon-
strated that the RING motif of BRCA1 serves as the
binding site for the E2 enzyme UB2D3 (UbcH5c) and that
BRCA1/BARD1 together have an increased ability to con-
jugate UBIQ with UB2D3 in vitro than BRCA1 alone.
Rachel Klevit's group determined that several of the can-
cer-predisposing mutations in BRCA1 result in defective
E3 activity in vitro by disrupting BRCA1/BARD1 het-
erodimer formation or by altering the RING domain
structure of BRCA1 [129-131]. Cell-based overexpression
experiments demonstrated that the abundance of each
protein is dependent upon the presence of its binding
partner.
Phosphorylated RBBP8 (CtIP) is a reported substrate for
ubiquitylation by BRCA1 [132]. Originally identified in a
yeast two-hybrid screen for proteins that bind to the
BRCA1 C-terminus (BRCT) domain of BRCA1 and con-
firmed through in vitro binding experiments, RBBP8 inter-
acts with BRCA1 during G2 of the cell cycle [133-135].
Cell-based and in vitro ubiquitylation assays have demon-
strated that BRCA1 ubiquitylates phosphorylated RBBP8
[132]. Rather than promoting RBBP8 degradation by the
proteasome, UBIQ modification may cause RBBP8 to
associate with chromatin following DNA damage and to
regulate the G2/M transition of the cell cycle, as deter-
mined by cellular localization studies in response to DNA
damage [132,136]. BRCA1 could also be associated with
the DNA repair activities of the Fanconi anemia (FA) path-
way (see next section), as both physical and functionalBMC Biochemistry 2008, 9(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/9/S1/S7
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interactions between BRCA1 and FA complex proteins in
response to DNA damage have been described [137].
The Fanconi anemia pathway involves a ubiquitin ligase complex and 
is associated with increased cancer susceptibility
As described in the [138], studies on the rare autosomal
recessive genetic disorder known as Fanconi anemia (FA)
have identified a pathway crucial for the cellular response
to DNA damage [139-151]. Alterations in this pathway
promote increased susceptibility to cancer and have been
associated with a wide variety of tumor types, even in non-
FA patients [152-166]. Upon DNA damage, two proteins
in this pathway are mono-ubiquitylated; FACD2
(FANCD2) and FANCI [137,141], and recruited to chro-
matin within nuclear foci. These nuclear foci contain
other DNA repair proteins, suggesting that they are sites of
DNA damage [137,147,167-169].
The role and exact molecular mechanisms underlying the
regulation of FACD2 and FANCI mono-ubiquitylation are
unclear; however, a protein complex (the FA core com-
plex) contains a subunit known as FANCL that contains a
RING motif and likely confers their modification [140].
Work from the D'Andrea and Dutta laboratories identi-
fied a ubiquitin-conjugating enzyme, UBE2T, that binds
directly to FANCL in a yeast two-hybrid screen and
through in vitro pull-down experiments with bacterially
expressed proteins [170]. SiRNA depletion of UBE2T in
U2OS cells diminished the mono-ubiquitylation of
FACD2 in response to DNA damage and promoted the
formation of abnormal chromosomes [170]. An siRNA
screen for DUBs important for removing UBIQ from
FACD2 implicated UBP1 (USP1) as an enzyme that could
attenuate the role of FACD2 in DNA damage repair [171].
Viruses exploit the ubiquitin system
Viruses utilize clever mechanisms to exploit their host to
facilitate their own propagation. Modification of proteins
with UBIQ during infection promotes viral replication
and immune response evasion, suggesting potential anti-
viral strategies.
HIV encodes proteins that hijack cellular cullin-RING ubiquitin ligases
The rapid evolution of viral subtypes resistant to available
treatments suggests that there is still significant need for
new anti-HIV therapeutics. Two HIV-encoded proteins,
VIF and VPU, interact with distinct cullin-RING ubiquitin
ligases to hijack their activity and promote the ubiquityla-
tion of cellular proteins.
VIF interacts directly with a cellular cytidine deaminase,
ABC3G (APOBEC3G), and facilitates its proteasome-
dependent degradation [172,173]. In the absence of VIF,
ABC3G is packaged into progeny virion particles, which
renders them defective in replication [172,174,175].
Immunoprecipitation of hemagglutinin (HA)-tagged VIF
from H9 cells (human T-cell line) infected with engi-
neered HIV, followed by mass spectrometry, demon-
strated that VIF associates with CUL5, ELOB (elongin B)
and ELOC (elongin C). Western blotting was used to con-
firm the presence of all proteins including RBX1 [176]. In
vitro ubiquitylation of ABC3G purified from transfected
cells has been demonstrated using a reconstituted com-
plex of these proteins from baculovirus-infected insect
cells [177,178].
The CD4 cell surface receptor found on a subclass of T-
cells is downregulated through the activity of VPU
[179,180]. As CD4 is a co-receptor for HIV entry into cells,
this downregulation could optimize viral replication by
blocking further infection, allow for progeny viral parti-
cles to be efficiently released, and promote immune
response evasion [179]. Co-expression of VPU and CD4
in HeLa cells results in the degradation of CD4, which can
be blocked by the proteasome inhibitor MG132 [181].
Work by Margottin et al. originally identified the F-box
protein β-TRCP from a yeast two-hybrid screen for VPU-
interacting proteins [182]. After demonstrating the forma-
tion of the ternary CD4/VPU/β-TRCP complex by overex-
pressing these proteins in HeLa cells, the authors showed
that the F-box motif of β-TRCP is necessary for CD4 deg-
radation in these cells. It was later reported that VPU may
block the ubiquitylation of IKBA (Iκbα) and CTNB1,
which are phosphorylation-dependent cellular substrates
of SCFβ-TRCP, and that VPU itself may also be ubiquitylated
by this complex [183-186].
Herpesviruses encode ubiquitin ligases and modulate cellular 
ubiquitin ligases
Herpesviruses often employ strategies to utilize the host
cell's ubiquitin system for their own benefit. The gamma-
herpesvirus Kaposi's sarcoma herpesvirus (KSHV, alterna-
tively human herpesvirus types 8, HHV8), which is
associated with AIDS-related cancer (see [187]), encodes
two ubiquitin ligases; K3 (MIR1) and K5 (MIR2), which
downregulate a wide range of immunoreceptors (MHC
class I, ICAM1, CD86, CD1D (CD1d)) from the surface of
infected cells [188-193]. This mechanism could promote
immune system evasion by blocking detection by cyto-
toxic T-lymphocytes.
The molecular details of how K3 and K5 promote immu-
noreceptor downregulation through the ubiquitin system
are beginning to emerge. Laurent Coscoy's group recently
reported the unexpected observation that transient expres-
sion of K3 in human BJAB cells stably expressing the MHC
class I allele HLA.B7 can lead to downregulation of this
receptor in the absence of cytoplasmic lysine residues if a
cysteine residue is present [17]. Paul Lehner's laboratory
used siRNA experiments to identify UBC13 and UB2D2/BMC Biochemistry 2008, 9(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/9/S1/S7
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UB2D3 (UbcH5b/c) as the E2 enzymes important for K3-
dependent downregulation of MHC class I [194]. This
study suggests that K3-mediated modification of MHC
class I occurs through a sequential mechanism in which
Lys63-linked UBIQ chains synthesized by UBC13 are
added after initial mono-ubiquitylation by UB2D2/
UB2D3, thereby promoting receptor endocytosis and lys-
osomal targeting.
Herpesviruses also encode proteins that modulate cellular
ubiquitin ligase activity, such as LMP1 (latent membrane
protein 1) – encoded by EBV. LMP1 is required for EBV
latency in B-cells and is sufficient to induce transforma-
tion [195,196]. Recent work from Joseph Pagano's labora-
tory has uncovered differential effects of LMP1 on the
SIAH1 ubiquitin ligase, dependent upon cell type [197-
199]. EBV-positive B-cells expressing LMP1 or cells tran-
siently transfected to express LMP1 manifest an upregula-
tion of CTNB1, a component of the Wnt  signaling
pathway whose increased stability has been associated
with cancer (see section on Colorectal cancers are associated
with defects in the regulation of CTNB1 (β-catenin) stability
through mutations in adenomatous polyposis coli) [197]. This
observation was attributed to LMP1-mediated downregu-
lation of SIAH1, a component of a RING ubiquitin ligase
complex that regulates CTNB1 stability, at the transcrip-
tional level [120,121]. By contrast, human epithelial cells
expressing LMP1 manifest increased SIAH1 protein levels
and a resulting decrease in the SIAH1 substrates prolyl
hydroxylases 1 and 3 (PHD1, PHD3 [also known as
EGLN2 and EGLN3]) [198,200]. These decreases promote
the stability of the transcription factor HIF1A as it cannot
be hydroxylated, an event required for its association with
the VHL-containing ubiquitin ligase (see section on Cul-
lin-RING ubiquitin ligases and the APC/C regulate cellular
proliferation).
Neurodegenerative diseases often have associated 
impairment of the ubiquitin system
The formation of protein aggregates containing UBIQ has
long been associated with neurodegenerative diseases
such as Parkinson's, Alzheimer's, Huntington's, and oth-
ers. For example, polyglutamine repeat expansion in pro-
teins associated with Huntington's disease and the
spinocerebellar ataxias could promote the formation of
protein aggregates that are resistant to degradation by the
proteasome and also impair proteasome function (see
[201]). Similarly in Alzheimer's disease, the formation of
neurofibrillary tangles and plaques associated with amy-
loid-β protein aggregation and/or ubiquitylated TAU
(tau) accumulation could impair proteasome function
(see [202]).
Another example is found with autosomal-recessive juve-
nile Parkinson's disease, in which mutations in the ubiq-
uitin ligase PRKN2 (parkin) manifest as defects in its
ligase activity in vitro [203-205], suggesting that accumu-
lation of its substrates could contribute to disease devel-
opment.
Metabolic diseases such as diabetes could have associated 
defects in aspects of the ubiquitin system
The exact relationships between the ubiquitin system and
metabolic processes are only beginning to be understood
(see [206]). Insulin resistance, associated with diabetes
and obesity, manifests as defects in sensing and signaling
mechanisms. The ubiquitin system has been associated
with insulin signaling through regulating the stability of
insulin receptor substrate (IRS) proteins.
IRS proteins serve as adapter molecules, functioning
between receptor tyrosine kinases and downstream sign-
aling molecules. IRS2 in particular has a crucial function
in controlling the growth and survival of pancreatic β-cells
– the body's source of insulin. Irs2 knockout mice are dia-
betic and exhibit dramatic reduction in β-cell mass, and
decreasing IRS2 expression via siRNA in β-cells promotes
apoptosis and decreased cell survival [207]. Thus, signal-
ing through IRS2 has a crucial function in regulating the
body's response to changes in glucose.
IRS2 function is regulated by phosphorylation and UBIQ-
mediated degradation by the proteasome [208,209]. In
pancreatic β-cells, activation of the kinase FRAP (mTOR),
as demonstrated by adenoviral delivery of constitutively
active FRAP to rat INS-1 cells, promotes IRS2 phosphor-
ylation and degradation by the proteasome [210]. IRS2
interacts with suppressors of cytokine signaling (SOCS)
proteins SOCS1 and SOCS3 in human HEK293 cells,
mouse 3T3-L1 adipocytes, and mouse hepatocytes [210].
These proteins contain a 'SOCS box' motif, which pro-
motes their interaction with ELOC, a component of a cul-
lin-based ubiquitin ligase, which in turn recruits IRS2 for
ubiquitylation and targets it for degradation by the pro-
teasome [211]. Future studies aimed at understanding
how IRS2 abundance relates to mechanisms of glucose
sensing may lead to novel approaches for combating the
growing epidemic of diabetes.
Muscle wasting disorders have increases in ubiquitin 
system function
Decreases in skeletal muscle mass associated with aging,
cancer, disuse and other physiological circumstances
occur through proteolytic mechanisms involving calpain
proteases and UBIQ-dependent protein degradation (see
[212]).
Experimental evidence suggests that numerous genes of
the ubiquitin system are upregulated during muscle atro-
phy, including those encoding a muscle-specific ubiquitinBMC Biochemistry 2008, 9(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/9/S1/S7
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ligase (TRI63, also known as MuRF1) and a potential sub-
strate receptor for SCF (the F-box protein FBX32, also
known as MAFbx and Atrogin-1) [213]. Knockout studies
in mice performed by Regeneron for each of these genes
support their crucial roles in promoting muscle atrophy
[213]. Whereas TRI63 deletion results in 36% sparing of
muscle mass loss after denervation of the right hindlimb
muscle of mice, FBX32 deletion allows for 56% sparing
under similar experimental conditions when compared
with controls.
Potential substrates for these ubiquitin ligases are only
beginning to be identified. TRI63 may target TITIN (titin),
a protein implicated in myofibril organization for degra-
dation [214]. The binding between TRI63 and the C-ter-
minal region of TITIN was originally identified by yeast
two-hybrid studies [215]. FBX32, as a substrate receptor
for SCF, has been proposed to facilitate the ubiquitylation
of the calmodulin-dependent phosphatase calcineurin A
and MyoD, a transcription factor involved in myogenic
differentiation [216,217]. Cam Patterson's group identi-
fied calcineurin A through a yeast two-hybrid screen using
FBX32 as bait and validated this interaction through in
vitro and cell-based experiments and overexpression stud-
ies in mice. Using MyoD as bait in a yeast two-hybrid
screen, FBX32 was identified as an interacting protein, and
a variety of cell-based and in vitro experiments demon-
strated binding, ubiquitylation and turnover dependent
upon this interaction [217].
UBIQ is involved in NFκB activation to regulate 
inflammation and innate immunity
Numerous distinct pathways can promote the activation
of NFκB in response to distinct stimuli (such inflamma-
tory cytokines, DNA damaging agents and microbes) and
UBIQ has diverse and complex roles in this process. Con-
ventional roles for UBIQ, such as targeting the NFκB
inhibitor IKBA for degradation by the proteasome
[118,218-220] and the proteasome-dependent processing
of NFκB precursor proteins [221,222], are mixed with
non-proteolytic functions in regulating specific signaling
pathways [28,30]. Also, these signaling mechanisms can
be attenuated by specifically associated DUBs [223]. This
complexity provides distinct levels of regulation of NFκB
activation that could allow for the modulation of this
process associated with a wide range of diseases. NFκB
activation through TNR11 (receptor activator of NFκB,
RANK), for example, has an important role in bone home-
ostasis and is associated with diseases such as osteoporo-
sis, rheumatoid arthritis and Paget's disease of bone (see
[224]).
The importance of regulating NFκB signaling through dis-
tinct pathways is highlighted by the tumors associated
with the genetic disorder cylindromatosis [225]. Afflicted
individuals contain mutations in a DUB known as CYLD.
This enzyme functions downstream of the tumor necrosis
factor α receptor and is involved in attenuating NFκB acti-
vation by deubiquitylating the signaling molecules
TRAF2, TRAF6 and TRAF7 [226-228]. The regulation of
TRAF2 signaling by CYLD was identified by screening an
RNAi library targeting DUBs for ones that attenuate NFκB
activation [227] and through a two-hybrid screen for pro-
teins that interact with the regulatory subunit of the IκB
kinase complex that could also bind to TRAF2 [228]. Later
work studying signaling through the toll-like receptor 2
(TLR2) performed cell-based experiments to demonstrate
that CYLD binds to TRAF6 and TRAF7 and that depletion
of CYLD increases the ability of transfected TRAF6 or
TRAF7 to activate an NFκB-dependent reporter gene
[226].
UBIQ-dependent ion channel stability has implications in 
cardiovascular diseases
Alterations in ion channel stability have been associated
with cystic fibrosis and Liddle's syndrome. Cystic fibrosis,
one of the most common genetic diseases, is characterized
by a wide array of recessive mutations in CFTR (cystic
fibrosis transmembrane conductance regulator), a Cl- ion
channel protein (see [229]). These mutations promote
CFTR misfolding and subsequent clearance through pro-
tein quality control pathways of the ubiquitin system.
Exactly how CFTR downregulation promotes lung disease
is unclear. By contrast, Liddle's syndrome is associated
with increased stability of an epithelial Na+  channel
(ENaC, see [230]). This autosomal dominant disorder is
characterized by mutations in ENaC that block its recog-
nition by the HECT ligase NEDD4 (see [8]), which pro-
motes ENaC accumulation at the cell surface. Alterations
of proper ionic balance in the kidney through increases in
ENaC may increase blood volume and blood pressure,
promoting cardiovascular disease [231,232].
Lead discovery
Current drug discovery activities focused on the ubiquitin 
system
The 26S proteasome is the only validated therapeutic tar-
get of the ubiquitin system, with a single commercially
available drug known as Velcade. Current drug discovery
activities related to the ubiquitin system focus on three
major areas: (i) expanding indications of proteasome
inhibition in therapy, (ii) developing proteasome inhibi-
tors targeting different activities of the proteasome and
with improved bio-availability, and (iii) validating the
potential of other targets of the ubiquitin system.
Proteasome inhibition is a treatment for cancer
Changes in proteasome function have been implicated in
the development of various diseases (see [233]). In 2003,
a small molecule proteasome inhibitor known as VelcadeBMC Biochemistry 2008, 9(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/9/S1/S7
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(bortezomib by Millennium Pharmaceuticals) was
approved by the FDA for the treatment of relapsed or
refractory multiple myeloma (see [234]). Velcade is a
boronic acid derivative (chemical name [(1R)-3-methyl-
1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)
amino]propyl]amino]butyl] boronic acid) that is a revers-
ible inhibitor of the chymotrypsin-like activity of the 26S
proteasome [235].
Efforts are underway by several other companies to
develop inhibitors that target distinct activities of the pro-
teasome. One such company is Proteolix, which has
developed PR-171, a synthetic analog of epoxomycin that
irreversibly inhibits the chymotryptic site of the proteas-
ome. Treatment of xenograft models over the course of
two days demonstrated that PR-171 has a stronger anti-
tumor effect than Velcade [236]. Phase I trials are cur-
rently underway for PR-171 to evaluate its role in treating
multiple myelomas and non-Hodgkin's lymphoma.
Another proteasome-targeting drug that is currently in
Phase I clinical trials is salinosporamide A (NPI-0052),
developed by Nereus Pharmaceuticals. Pre-clinical studies
have demonstrated that NPI-0052 achieves a higher and
more sustained level of proteasome inhibition when com-
pared with Velcade [237]. It is also well tolerated and
improves the response of multi-drug treatment of a colon
cancer xenograft model [237]. These two drugs highlight
the therapeutic potential of proteasome inhibition when
treating various cancerous states. Indeed, Cytomics Sys-
tems, Eisai, Novartis AG, Bristol-Myers Squibb, Cell Ther-
apeutics, Cephalon and Ergon Pharmaceuticals are all
developing proteasome inhibitors for this purpose.
Small molecules can promote P53 (p53) stability
As described in the section Cancer is associated with altera-
tions in UBIQ-dependent regulation, MDM2 is a RING ubiq-
uitin ligase that has a crucial role in regulating P53
stability. The development of inhibitors that disrupt this
interaction will play a major role in the regulation of cell
cycle progression and potentially the treatment of cancer.
One group of small molecules currently in development is
the nutlins, by Roche. These represent the first small mol-
ecules that can interfere with the ability of MDM2 to
mediate P53 ubiquitylation [238]. Nutlins bind to the
pocket domain of P53, and inhibit xenograft tumor
growth in vivo with no obvious toxicity. They activate the
P53 pathway at a range of 1–3 μM, stimulating cell cycle
arrest and apoptosis in tumor cells. By contrast, treatment
of untransformed cells results in cell cycle arrest, but no
apoptosis [239].
RITA [2,5-bis(5-hydroxymethyl-2-thienyl)furan
(NSC652287)], isolated from a screen by the National
Cancer Institute (NCI) [240,241], is another compound
that has been shown to regulate the interaction between
MDM2 and P53. RITA also induces apoptosis in human
tumor cells, but has little effect on normal cells. It has
been proposed to bind the N-terminus of P53; thereby
causing a conformational change that prevents MDM2
binding. However, the sensitivity of human fibroblasts to
RITA is varied and depends on the expression level of
oncogenes such as MYC (C-MYC) [242]. RITA, as with
nutlins, has a significant antitumor effect on mice carrying
human tumor xenografts, without apparent toxicity [243],
and both are in pre-clinical development. The therapeutic
potential of these and other molecules targeting this
important regulatory mechanism are currently being
explored. Nevertheless, they represent an important class
of molecules, which block substrate recognition by a
ubiquitin ligase through interfering with a protein-protein
interaction interface.
Inhibition of E1 may be a viable therapeutic target
If inhibiting the proteasome has therapeutic utility, then
perhaps targeting UBIQ (ubiquitin) activation by E1
might also be beneficial. Both Millennium Pharmaceuti-
cals and Rigel Pharmaceuticals have filed patents disclos-
ing their discovery of E1 inhibitors (Millennium patent:
WO2006084281 [244], Rigel patent: WO2005037845
[245], see [246]). These small molecule inhibitors of
UBIQ activation may also have potential as cancer thera-
peutics.
Ubiquitin ligases and deubiquitylating enzymes are emerging 
therapeutic targets
Proteasome inhibition or E1 inhibition appear to be glo-
bal approaches to controlling protein activities regulated
by UBIQ. As a result, efforts are ongoing to selectively tar-
get enzymes involved in specific ubiquitylation pathways.
Ubiquitin ligases and deubiquitylating enzymes (DUBs)
have gained the most attention due to their direct roles in
regulating their recognized protein's stability. However,
the complexity of protein ubiquitylation coupled with the
absence of catalytic pockets for small molecule binding
has made targeting ubiquitin ligases challenging. Never-
theless, Rigel Pharmaceuticals is currently characterizing
ubiquitin ligases as potential therapeutic targets. The com-
pany has a broad, on-going program to explore the role of
specific ubiquitin ligases in oncology, inflammation,
virology and metabolism – with Merck and Daiichi as col-
laborators. Other companies such as Celgene, Amgen and
Genentech also have programs exploring ubiquitin ligases
for clinical indications. Thus, the flurry of activity sur-
rounding ubiquitin ligases supports their potential thera-
peutic importance for developing new treatments for a
wide variety of conditions.
In contrast to ubiquitin ligases, DUBs have a more simple
mechanism of action and a catalytic pocket for targeted
binding of small molecules. Hybrigenics recently dis-BMC Biochemistry 2008, 9(Suppl 1):S7 http://www.biomedcentral.com/1471-2091/9/S1/S7
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closed the discovery of several small molecules that can
inhibit UBP7 (USP7) (HBX 41108) and UBP8 (USP8)
(HBX 90397, HBX 90659), which may have oncology
applications.
New frontiers in drug discovery for the ubiquitin 
system
Our understanding of the complexities of the ubiquitin
system and its involvement in aspects of physiology is still
developing and (perhaps justifiably) so are efforts to dis-
cover drugs targeting its enzymes. Here, I summarize
some of the current challenges and opportunities that
could allow for the potential of the enzymes of the ubiq-
uitin system to be realized as therapeutic targets.
How can ubiquitin ligase activity be inhibited?
Ubiquitin ligases may represent the best target class of the
ubiquitin system due to their intrinsic specificity for par-
ticular protein substrates. The vast majority of ubiquitin
ligases are RING-type. These appear to function primarily
as scaffolds to position the substrate to be modified in
close juxtaposition with the ubiquitin-conjugating
enzyme to promote covalent UBIQ (ubiquitin) transfer
[247]. Thus, means to modulate ubiquitin ligase activity
may necessarily focus on targeting protein-protein inter-
faces. Whereas the MDM2-P53 (p53) interface can be dis-
rupted by small molecules, is this possible for other E3-
substrate interactions? Do different RING motifs (the
binding site for the ubiquitin-conjugating enzyme) look
different enough to be considered as targets? If so, how
can they be targeted? HECT (homologous to E6AP C-ter-
minus) domain ligases, by contrast, have a catalytic func-
tion and may undergo conformational changes [248],
suggesting that, at least superficially, they could be more
amenable.
Can we harness ubiquitin ligases to artificially target 
proteins for ubiquitylation?
Increased protein stability correlates with several disease
phenotypes. For some of these cases, defects in upstream
signaling results in impaired substrate targeting to ubiqui-
tin ligases. In other cases, the ubiquitin ligase itself has
functional defects. These observations suggest that artifi-
cially recruiting a protein to a ubiquitin ligase could be an
approach to restoring proper protein homeostasis.
Indeed, there are several reports supporting the potential
of this approach [249-251]. One such strategy has
involved the development of a chimeric protein or 'Pro-
TaC' (proteolysis targeting chimeric molecule), which tar-
gets the protein to the SCFβ-TRCP ubiquitin ligase. SCFβ-TRCP
then targets the protein for ubiquitylation, followed by
proteasomal degradation. ProTaC consists of a SCFβ-TRCP-
binding IKBA (IκBα) phosphopeptide linked to a domain
that binds the targeted protein [252]. Further develop-
ment of this technology could have the potential to realize
a powerful and specific tool for the treatment of diseases
such as cancer.
Are ubiquitin-conjugating enzymes good therapeutic 
targets?
Whereas there are considerably fewer ubiquitin-conjugat-
ing enzymes than ubiquitin ligases, they may function in
specific ubiquitylation pathways. As they represent an
essential part of the ubiquitylation process, conferred
through their enzymatic activity, they may be reasonable
targets. However, these enzymes have a very highly con-
served enzymatic core and do not possess defined catalytic
pockets [253].
What other approaches should be considered?
Recent work identified small molecules known as ubistat-
ins that bind to Lys48-linked UBIQ chains in vitro and
block UBIQ-dependent protein degradation by the pro-
teasome [254]. Randy King's group at Harvard identified
ubistatins in a chemical genetic screen for small molecules
that stabilize Cyclin B in Xenopus extracts, and they were
subsequently shown to inhibit the degradation of the
yeast cyclin-dependent kinase inhibitor SIC1 (Sic1) in a
reconstituted in vitro system. NMR and in vitro binding
studies determined that these molecules bind specifically
to Lys48-linked UBIQ chains. Whilst these molecules are
not cell permeable and have unclear therapeutic potential,
they do represent a new approach for blocking protein
degradation.
Another direction could be to target mechanisms that reg-
ulate ubiquitin ligase assembly. The SCF ubiquitin ligase,
for example, is comprised of multiple subunits in which
substrate recognition is conferred by a variable receptor
subunit (F-box proteins) [53]. The assembly of specific
SCF complexes appears to be regulated at multiple levels
ranging from receptor abundance to post-translational
modification of its enzymatic core. As our knowledge of
the intricacies of the ubiquitin system continues to grow,
it is likely that we will uncover new regulatory mecha-
nisms associated with protein ubiquitylation.
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